{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:46:30Z","timestamp":1793533590343,"version":"4.5.0"},"reference-count":73,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Retinopathy of prematurity (ROP) is an alteration in the development of the immature retina vascularization that frequently occurs in premature infants and is one of the leading causes of childhood blindness worldwide. In threshold stage retinopathy, laser photocoagulation is the standard treatment, particularly in those located in zone II. However, this therapy destroys parts of the retina and can lead to significant eye complications later in life. For this reason, in the last few years, antivascular endothelial growth factor agents are being used as monotherapy or as coadjuvant with laser, especially in retinopathy located in zone I. More recently, the administration of oral propranolol has been used as prevention and\/or treatment of prethreshold retinopathy with encouraging results. This review provides an overview of the current evidence on newer treatment strategies for ROP.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/s-0040-1713181","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:36:52Z","timestamp":1592350612000},"page":"022-030","source":"Crossref","is-referenced-by-count":39,"title":["Update in the Treatment of Retinopathy of Prematurity"],"prefix":"10.1055","volume":"39","author":[{"given":"Aldo","family":"Bancalari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Concepcion, Concepcion, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Schade","sequence":"additional","affiliation":[{"name":"Ophthalmology Service, Guillermo Grant Benavente Hospital, Concepcion, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5409\/wjcp.v5.i1.35","article-title":"Retinopathy of prematurity: past, present and future","volume":"5","author":"P K Shah","year":"2016","journal-title":"World J Clin Pediatr"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clp.2013.02.001","article-title":"Retinopathy of prematurity-incidence today","volume":"40","author":"A Zin","year":"2013","journal-title":"Clin Perinatol"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"C Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","article-title":"Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs","volume":"115","author":"C Gilbert","year":"2005","journal-title":"Pediatrics"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0301-4738.33817","article-title":"Retinopathy of prematurity in Asian Indian babies weighing greater than 1,250 grams at birth: ten year data from a tertiary care center in a developing country","volume":"55","author":"A Vinekar","year":"2007","journal-title":"Indian J Ophthalmol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000322848","article-title":"A paradigm shift in the prevention of retinopathy of prematurity","volume":"100","author":"T S Raghuveer","year":"2011","journal-title":"Neonatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4067\/S0370-41062000000200006","article-title":"Retinopathy of prematurity: incidence and associated factors","volume":"71","author":"A Bancalari","year":"2000","journal-title":"Rev Chil Pediatr"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"W M Fierson","year":"2018","journal-title":"Pediatrics"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/aos.12049","article-title":"The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge","volume":"92","author":"G Cavallaro","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000444901","article-title":"Retinopathy of prematurity: therapeutic strategies based on pathophysiology","volume":"109","author":"R Cayabyab","year":"2016","journal-title":"Neonatology"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archopht.1994.01090140028007","article-title":"Laser therapy for retinopathy of prematurity","volume":"112","author":"Laser ROP Study Group","year":"1994","journal-title":"Arch Ophthalmol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0161-6420(93)31664-7","article-title":"Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study","volume":"100","author":"D G Hunter","year":"1993","journal-title":"Ophthalmology"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/archopht.1992.01080240054029","article-title":"Diode laser photocoagulation for retinopathy of prematurity. Preliminary results","volume":"110","author":"J A McNamara","year":"1992","journal-title":"Arch Ophthalmol"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(01)01015-6","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome","volume":"109","author":"B P Connolly","year":"2002","journal-title":"Ophthalmology"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0161-6420(01)01017-X","article-title":"A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome","volume":"109","author":"E Y Ng","year":"2002","journal-title":"Ophthalmology"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"D K Wallace","year":"2013","journal-title":"Clin Perinatol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"J C Law","year":"2010","journal-title":"J AAPOS"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"H A Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.semperi.2019.05.011","article-title":"Antivascular endothelial growth factor intravitreal therapy for retinopathy of prematurity","volume":"43","author":"D K VanderVeen","year":"2019","journal-title":"Semin Perinatol"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"T Shih","year":"2006","journal-title":"Clin Ther"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"R L Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4067\/S0370-41062013000300008","article-title":"Tratamiento de la retinopat\u00eda del prematuro con bevacizumab intrav\u00edtreo","volume":"84","author":"A Bancalari","year":"2013","journal-title":"Rev Chil Pediatr"},{"issue":"02","key":"ref27","first-page":"160","article-title":"Intravitreal bevacizumab as single drug therapy for retinopathy of prematurity in 12 patients","volume":"112","author":"A Bancalari M","year":"2014","journal-title":"Arch Argent Pediatr"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"E J Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"A Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"D K Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"01","key":"ref31","first-page":"29","article-title":"[Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]","volume":"68","author":"R Autrata","year":"2012","journal-title":"Cesk Slov Oftalmol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"M Gunay","year":"2017","journal-title":"Curr Eye Res"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"E A Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"E U Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"M Gunay","year":"2015","journal-title":"Arq Bras Oftalmol"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"M M Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"A Stahl","year":"2019","journal-title":"Lancet"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"W CH Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Z Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"ref40","first-page":"127","article-title":"[Complications of intravitreal injections--own experience]","volume":"113","author":"A Jamrozy-Witkowska","year":"2011","journal-title":"Klin Oczna"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaapos.2017.12.005","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"D Morrison","year":"2018","journal-title":"J AAPOS"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"S Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"B Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"J Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"K A Kennedy","year":"2018","journal-title":"J AAPOS"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archophthalmol.2010.234","article-title":"Natural history of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden","volume":"128","author":"D Austeng","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IAE.0000000000000270","article-title":"Natural history of retinopathy of prematurity: two-year outcomes of a prospective study","volume":"35","author":"Y H Chen","year":"2015","journal-title":"Retina"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jpm-2015-0357","article-title":"Oral propranolol in early stages of retinopathy of prematurity","volume":"44","author":"A Bancalari","year":"2016","journal-title":"J Perinat Med"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2013.1476","article-title":"Attenuation of choroidal neovascularization by \u03b2(2)-adrenoreceptor antagonism","volume":"131","author":"J A Lavine","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade","volume":"52","author":"C Ristori","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.preteyeres.2014.06.001","article-title":"The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases","volume":"42","author":"G Casini","year":"2014","journal-title":"Prog Retin Eye Res"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/adc.2010.208884","article-title":"Propranolol for infantile haemangiomas: a review","volume":"96","author":"E Starkey","year":"2011","journal-title":"Arch Dis Child"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy","volume":"23","author":"J Tang","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/med.21336","article-title":"Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the \u03b2-adrenergic system","volume":"35","author":"L Filippi","year":"2015","journal-title":"Med Res Rev"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1525-1470.2009.00975.x","article-title":"Propranolol treatment for hemangioma of infancy: risks and recommendations","volume":"26","author":"L P Lawley","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"issue":"06","key":"ref57","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives","volume":"163","author":"L Filippi","year":"2013","journal-title":"J Pediatr"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","article-title":"Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study","volume":"98","author":"I R Makhoul","year":"2013","journal-title":"Arch Dis Child"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02713683.2016.1158272","article-title":"The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index","volume":"42","author":"L Korkmaz","year":"2017","journal-title":"Curr Eye Res"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"F389","DOI":"10.1136\/archdischild-2016-311548","article-title":"Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial)","volume":"102","author":"K P Sanghvi","year":"2017","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/pr.2016.230","article-title":"Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial","volume":"81","author":"L Filippi","year":"2017","journal-title":"Pediatr Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fped.2019.00180","article-title":"Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study","volume":"7","author":"L Filippi","year":"2019","journal-title":"Front Pediatr"},{"key":"ref63","first-page":"2665","article-title":"Treatment of retinopathy of prematurity with propranolol: randomized control trial","author":"A Bancalari","year":"2018","journal-title":"E-PAS"},{"issue":"07","key":"ref64","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","article-title":"Treatment of infantile haemangiomas: recommendations of a European expert group","volume":"174","author":"P H Hoeger","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000381659","article-title":"Oral propranolol: a new treatment for infants with retinopathy of prematurity?","volume":"108","author":"C B\u00fchrer","year":"2015","journal-title":"Neonatology"},{"key":"ref66","first-page":"CD011893","article-title":"Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants","volume":"3","author":"S Kaempfen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41372-019-0503-x","article-title":"Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis","volume":"39","author":"A Stritzke","year":"2019","journal-title":"J Perinatol"},{"issue":"07","key":"ref68","doi-asserted-by":"crossref","first-page":"e021749","DOI":"10.1136\/bmjopen-2018-021749","article-title":"Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial","volume":"8","author":"C B\u00fchrer","year":"2018","journal-title":"BMJ Open"},{"issue":"08","key":"ref69","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archopht.118.8.1121","article-title":"STOP-ROP results suggest selective use of supplemental oxygen for prethreshold ROP","volume":"118","author":"M D Mills","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"06","key":"ref70","doi-asserted-by":"crossref","first-page":"e1483","DOI":"10.1542\/peds.2009-2218","article-title":"High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis","volume":"125","author":"M L Chen","year":"2010","journal-title":"Pediatrics"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1542\/peds.105.2.295","article-title":"Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes","volume":"105","author":"The STOP-ROP Multicenter Study Group","year":"2000","journal-title":"Pediatrics"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/pr.2016.98","article-title":"Graded oxygen saturation targets and retinopathy of prematurity in extremely preterm infants","volume":"80","author":"R Cayabyab","year":"2016","journal-title":"Pediatr Res"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1167\/iovs.16-20822","article-title":"Use of a supplemental oxygen protocol to suppress progression of retinopathy of prematurity","volume":"58","author":"T T Colaizy","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.8.2.20","article-title":"Heated and humidified high flow nasal canal oxygen supplementation as an effective treatment for high-risk prethreshold retinopathy of prematurity","volume":"8","author":"X Zhang","year":"2019","journal-title":"Transl Vis Sci Technol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1713181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T23:47:35Z","timestamp":1640821655000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1713181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":73,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,12,29]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1713181","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]}}}